Voyageur Pharmaceuticals Ltd. News
-
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
June 18, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (“Voyageur” or the “Company”), a Canadian…
-
Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
June 10, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”) announces the submission of…
-
Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
June 05, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade…
-
Voyageur Announces Filing Of Amended And Restated Offering Document
May 28, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade…
-
Voyageur Announces Update To Non-Brokered Life Offering
May 1, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade…
-
Voyageur Announces Shares for Debt Settlement and Stock Option Repricing
April 17, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade…
-
Voyageur Announces Non-Brokered Life Offering
March 25, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade…
-
Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
March 16, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (the “Company” or “Voyageur”), a…
-
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Purity Exceeding Pharmaceutical Grade, 98.8% BaSO4 Moving on to Stage 2 of the Alberta Innovates AICE-Market Access Program …
-
Voyageur Pharmaceuticals Announces Collaboration with Bayer
February 23, 2026 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”) a Canadian developer of…
